Epinephrine

證據等級: L5

預測適應症: 4 個

Epinephrine: From Anaphylaxis to Obstructive Lung Disease

One-Sentence Summary

Epinephrine (adrenaline) is a well-established catecholamine used globally as first-line emergency treatment for anaphylaxis and cardiac resuscitation, though it currently holds no CBG-MEB marketing authorization in the Netherlands. The TxGNN model predicts it may be effective for Obstructive Lung Disease (including asthma exacerbations and viral bronchiolitis), with 8 directly relevant clinical trials and 20 publications currently supporting this direction. This prediction receives an L1 evidence rating, based on multiple completed Phase 3 randomized controlled trials directly studying epinephrine in obstructive airway conditions.

Quick Overview

Item	Content
Original Indication	Anaphylaxis & cardiac resuscitation (no CBG-MEB Netherlands authorization)
Predicted New Indication	Obstructive Lung Disease
TxGNN Prediction Score	99.71%
Evidence Level	L1
NL Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Epinephrine is a naturally occurring catecholamine that acts simultaneously on α- and β-adrenergic receptors. When administered by inhalation, β2-adrenergic receptor stimulation produces potent bronchial smooth muscle relaxation, directly reversing airflow obstruction. Concurrent α1-adrenergic receptor activation causes vasoconstriction of mucosal blood vessels, reducing airway oedema and microvascular leakage — both core pathological features of obstructive lung disease, whether in acute asthma exacerbations, viral bronchiolitis in infants, or croup.

Note: Detailed mechanism of action data from DrugBank is currently unavailable for this evaluation. The mechanistic description above is based on established pharmacological knowledge of epinephrine’s well-characterized adrenergic receptor profile.

The connection between epinephrine’s primary emergency indication (anaphylaxis) and obstructive lung disease is pharmacologically direct: epinephrine reverses bronchospasm in anaphylaxis through exactly the same β2-mediated pathway as it would in asthma. Nebulized racemic epinephrine has been used clinically for decades in acute management of croup and viral bronchiolitis in children, and in the United States an epinephrine HFA metered-dose inhaler (Primatene Mist) is available over-the-counter for intermittent asthma — providing an international regulatory precedent. The TxGNN model’s prediction therefore converges with decades of clinical practice and mechanistic evidence, even though formal Netherlands (CBG-MEB) or EMA-wide authorization for this indication does not yet exist.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01460511	Phase 3	Completed	70	Multi-center double-blind RCT: E004 epinephrine inhalation aerosol (HFA-MDI) vs. placebo in children aged 4–11 with asthma — directly evaluates efficacy and safety of epinephrine inhaler for obstructive airway disease
NCT03567473	Phase 3	Completed	864	Multicentre RCT: inhaled epinephrine + oral dexamethasone vs. double placebo in infants with bronchiolitis; primary endpoint: hospitalization rate over 7 days
NCT00116584	Phase 3	Completed	72	Heliox-driven vs. air-driven nebulized racemic epinephrine in moderate-to-severe pediatric bronchiolitis in the emergency department; assesses speed of airway improvement
NCT01300325	Phase 4	Completed	136	RCT: nebulized 3% hypertonic saline + epinephrine vs. normal saline + epinephrine in RSV bronchiolitis hospitalizations; direct evidence for epinephrine combination regimen
NCT01834820	Phase 4	Completed	120	Pilot RCT: epinephrine + dexamethasone + hypertonic saline for infant bronchiolitis; evaluates hospital admission rate reduction with combined treatment strategy
NCT04207840	Phase 4	Completed	28	Three-way crossover PK study: Primatene Mist (inhaled epinephrine 0.25 mg) vs. IM epinephrine 0.30 mg vs. ProAir (albuterol) — systemic exposure comparison supporting inhaled epinephrine as an asthma bronchodilator route
NCT05363670	Phase 2	Completed	18	Four-period crossover RCT: intranasal epinephrine (ARS-1) as a needleless alternative for management of refractory asthma symptoms — evaluates bronchodilatory efficacy in persistent asthma
NCT01025648	Phase 1/2	Terminated	9	Dose-ranging study: E004 epinephrine HFA-MDI vs. placebo and active control (epinephrine CFC-MDI) in mild-to-moderate persistent asthma — terminated early; informed dose selection for subsequent Phase 3
NCT02586961	Phase 2/3	Terminated	195	Multicentre RCT: high-dose oral betamethasone + nebulized adrenaline vs. placebo in acute bronchiolitis presenting to pediatric emergency departments; terminated before completion
NCT01070225	Phase 4	Completed	14	Proof-of-concept study: reversal of acute β-blocker-induced bronchoconstriction using β-agonist rescue — contextualises adrenergic receptor modulation in airway obstruction management

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21678340	2011	Cochrane Systematic Review	Cochrane Database Syst Rev	Comprehensive meta-analysis of epinephrine vs. other bronchodilators for acute bronchiolitis; found epinephrine superior to placebo for short-term clinical outcomes and hospitalization reduction
14974006	2004	Cochrane Systematic Review	Cochrane Database Syst Rev	Foundational Cochrane review establishing that bronchodilators — including epinephrine — produce modest but statistically significant short-term benefit in mild-to-moderate bronchiolitis
4606289	1974	Clinical Study	Clin Pharmacol Ther	Direct comparative study of bronchodilator effects of terbutaline vs. epinephrine in obstructive lung disease — cornerstone pharmacological evidence for epinephrine in this indication
30488718	2019	Review	Expert Rev Respir Med	Systematic review of therapeutic strategies for pediatric bronchiolitis (2009–2018) with focused analysis of racemic epinephrine’s evidence base, including its role alongside hypertonic saline and high-flow oxygen
19135584	2009	Review	Pediatr Clin North Am	Evidence-based review of croup and acute bronchiolitis: confirms good evidence for temporary symptomatic benefit from nebulized adrenaline in both virally induced obstructive conditions
21486501	2011	Review	BMJ Clin Evid	BMJ clinical evidence review on bronchiolitis management, addressing epinephrine’s role in the most common cause of infant respiratory hospitalization
19450362	2007	Review	BMJ Clin Evid	Earlier BMJ evidence synthesis on bronchiolitis treatment; provides historical baseline for evaluating evolving evidence on epinephrine in infant obstructive lower respiratory disease
30856157	2019	Drug Bulletin	Med Lett Drugs Ther	Commentary on the regulatory return of Primatene Mist (OTC epinephrine HFA inhaler) to the US market, confirming regulatory precedent for epinephrine as a self-administered asthma bronchodilator
37088194	2023	Scoping Review	Ann Allergy Asthma Immunol	Scoping review of prehospital epinephrine for anaphylaxis in patients with comorbid asthma — highlights mechanistic overlap and safety of epinephrine across obstructive pulmonary and anaphylactic presentations
4551435	1972	Clinical Study	Ann Allergy	Early clinical evidence for nebulized bronchodilators — including epinephrine — in obstructive lung disease; establishes historical and mechanistic basis for inhaled epinephrine as a bronchodilator

Netherlands Market Information

Epinephrine currently holds no CBG-MEB marketing authorization in the Netherlands and is not registered as a commercial pharmaceutical product in the Dutch RVG (Register Geneesmiddelen) database. No RVG numbers are therefore available to list.

This does not mean epinephrine is absent from Dutch clinical practice: in hospital settings, epinephrine is routinely used for anaphylaxis management, cardiac resuscitation, and as a local anesthetic adjunct, typically supplied under hospital pharmacy authorization or as a ziekenhuisbereiding (hospital preparation). However, the absence of a formal commercial CBG-MEB registration means that any future application of epinephrine for obstructive lung disease in the Netherlands would require one of the following regulatory pathways:

A new Marketing Authorization Application (MAA) submitted to CBG-MEB directly or centrally via EMA
Compassionate use or named-patient supply under Dutch Medicines Act (Geneesmiddelenwet)
Off-label prescribing under the prescriber’s clinical responsibility, with documented medical justification per Dutch professional standards

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics / Samenvatting van de Productkenmerken) for complete safety information.

Formal safety data — including specific Dutch/EMA-registered warnings, contraindications, and drug interaction profiles — were not available in the current evidence pack. Based on the internationally recognized pharmacology of epinephrine, prescribers should be aware of the potential for cardiovascular adverse effects (including tachycardia, hypertension, and cardiac arrhythmias), particularly in elderly patients and those with pre-existing cardiac or thyroid conditions. These considerations are especially relevant when evaluating inhaled epinephrine for chronic obstructive lung disease use in a broader outpatient population beyond the current emergency-use context.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 3 RCTs — directly studying epinephrine in bronchiolitis and asthma — support an L1 evidence rating, and the TxGNN prediction score of 99.71% reflects a strong mechanistic and knowledge-graph alignment. However, the total absence of a Netherlands CBG-MEB marketing authorization, the lack of formal safety data in this evidence pack, and the need to differentiate acute-use from chronic-indication protocols necessitate a structured, gated approach before clinical or regulatory implementation.

To proceed, the following is needed:

Safety data gap closure: Obtain and review the SmPC from an internationally authorized epinephrine inhalation product (e.g., E004/Armstrong, Primatene Mist) to fulfil the DG001/DG002 data gaps identified in this pack
Mechanistic documentation: Source DrugBank API data for formal MOA characterization to support regulatory submission narratives
CBG-MEB pre-submission consultation: Determine the appropriate regulatory pathway (national MAA vs. EMA centralized) and discuss indication scope with the Medicines Evaluation Board
Risk Management Plan (RMP): Develop a pharmacovigilance plan covering cardiovascular adverse effects, particularly for paediatric and elderly populations
Formulation-specific strategy: Clarify which route of administration (nebulized, HFA-MDI, intranasal) is being developed, as each carries a distinct regulatory and clinical evidence profile
Comparative effectiveness assessment: Commission an HTA comparing epinephrine vs. standard-of-care bronchodilators (salbutamol, ipratropium) within the Dutch clinical context and Zorginstituut Nederland reimbursement framework
Clinical guideline alignment: Engage Dutch professional bodies (NVvR — Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose; NVK — Paediatric Society) to assess compatibility with existing national treatment guidelines for asthma and bronchiolitis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.